Gemcitabine plus nab-paclitaxel until progression or alternating with FOLFIRI.3, as first-line treatment for patients with metastatic pancreatic adenocarcinoma: The Federation Francophone de Cancérologie Digestive-PRODIGE 37 randomised phase II study (FIRGEMAX)

Publication | Closed Access

DOI

Citations

References

2020

Year

Yves Rinaldi, Anne‐Laure Pointet, F. Khemissa Akouz, Karine Le Malicot, Bidaut Wahiba, Samy Louafi, Alain Gratet, Laurent Miglianico, H. Laharie, Karine Bouhier Leporrier,

European Journal of Cancer

Pancreatic CancerGastrointestinal OncologyCancérologie Digestive-prodige 37MedicinePathologyPhase Ii StudyCancer TreatmentFederation FrancophoneOncologyRadiation OncologyCancer ResearchMolecular Oncology